Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0070 USD
Change Today 0.00 / 0.00%
Volume 10.0K
NVDL On Other Exchanges
As of 5:20 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

novadel pharma inc (NVDL) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/24/14 - $0.01
52 Week Low
09/24/14 - $0.0025
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVADEL PHARMA INC (NVDL)

novadel pharma inc (NVDL) Related Bloomberg News

View More Bloomberg News

novadel pharma inc (NVDL) Related Businessweek News

No Related Businessweek News Found

novadel pharma inc (NVDL) Details

NovaDel Pharma Inc., a specialty pharmaceutical company, develops oral spray formulations for marketed pharmaceuticals. The company’s proprietary technology enables delivery of drugs into the bloodstream leading to onset of action and patient benefits. Its oral spray candidates target angina, insomnia, erectile dysfunction, migraine headaches, and nausea. NovaDel Pharma’s marketed products include NitroMist for acute relief of an attack of angina pectoris, or acute prophylaxis of angina pectoris, due to coronary artery disease; and ZolpiMist for short-term treatment of insomnia. The company’s product candidates comprise Duromist, which is in preclinical development for erectile dysfunction; Zensana, which is in preclinical development for nausea; NVD-201, an oral spray formulation of sumatriptan in Phase 2/3 clinical trial to treat migraine headache; NVD-301, an oral spray formulation of midazolam in preclinical stage for the treatment of sedation during diagnostic, therapeutic, and endoscopic procedures; and ZolpiMist in Phase 1 clinical trial to treat middle of the night awakening. It has strategic license agreements with Talon Therapeutics, Inc., Kwang Dong Pharmaceuticals, and BioAlliance Pharma SA to develop and market Zensana; Manhattan Pharmaceuticals, Inc. for the company’s oral spray technology to deliver propofol for pre-procedural sedation; and Velcera Pharmaceuticals, Inc. for veterinary applications for marketed veterinary drugs. NovaDel Pharma also has agreements with Mist Acquisition, LLC, for the manufacturing and commercialization of the NitroMist lingual spray version of nitroglycerine; and ECR Pharmaceuticals Company, Inc. to manufacture and commercialize ZolpiMist. The company was formerly known as Flemington Pharmaceutical Corporation and changed its name to NovaDel Pharma Inc. in October 2002. NovaDel Pharma Inc. was founded in 1982 and is headquartered in Bridgewater, New Jersey.

novadel pharma inc (NVDL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

novadel pharma inc (NVDL) Key Developments

NovaDel Updates Pact with Amherst Pharmaceuticals

NovaDel Pharma has sold its remaining assets, which consisted of the ZolpiMist NDA, a license agreement and related global intellectual property to Amherst Pharmaceuticals, in exchange for assumption of approximately $2.2 million in fees owed to the FDA in relation to ZolpiMist. Amherst has not paid or entered into an agreement to pay the FDA the amount owed. Under the terms of agreement with Amherst, it has until Dec. 31, 2014, to pay the amount owed to the FDA. Amherst has informed that they are in the process of discussing this obligation with the FDA. Until Amherst settles this liability, NovaDel will remain contingently liable for these fees.

Novadel Pharma Is Considering Strategic Alternatives

Novadel Pharma Inc. (OTCPK:NVDL) is currently evaluating alternatives ranging from acquiring operating assets, in order to take advantage of the carry forwards, to liquidating the company.

Novadel Plans To Sell Assets

Novadel Pharma, Inc. announced in March 2014, that it is planning to sell all the assets with the intention of liquidating the company and distributing its remaining cash to shareholders.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVDL:US $0.01 USD 0.00

NVDL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVDL.
View Industry Companies

Industry Analysis


Industry Average

Valuation NVDL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVADEL PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at